The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial

Germline microRNA-disrupting biomarkers are functional biomarkers being studied to help guide treatment personalization in cancer. The work in this study is a hypothesis-generating evaluation of the KRAS-variant as a potential biomarker to help predict outcomes and toxicity in patients with head and neck cancer treated with radiation and cetuximab. Findings from this work suggest that these biomarkers may have the potential to differentiate patients at risk of acute versus late toxicity, supporting further study of these biomarkers in radiation studies.